Can a Limited Distribution Orphan Drug Not Be a Specialty Therapy?
We ran across a press release recently that looked a tad odd. It appeared that the FDA had approved a new therapy, Alkindi Sprinkle from
December 17, 2020
We ran across a press release recently that looked a tad odd. It appeared that the FDA had approved a new therapy, Alkindi Sprinkle from
Earlier this month the FDA approved yet another orphan drug, Orladeyo (berotralstat) from BioCryst Pharmaceuticals. It obtained an indication for the prevention of hereditary angioedema
Ok, we know you are ready for more catch up….. and it ain’t the red stuff. The FDA recently approved yet another expensive specialty pharmacy
Ok, catch up time.Looking back a couple of weeks….. the FDA approved yet another rare/orphan therapy (which is mostly all they they’ve approved in 2020!).
With the emergence of CV-19 just about every health care provider has been scrambling to do something to preserve their patient relationships. A patient that
The FDA recently revved up its approval engine waving yet another specialty pharmacy checkered flag for Zokinvy (lonafarnib) from Eiger BioPharmaceuticals. Zokinvy is indicated for
For a while we were seeing FDA specialty drugs approvals on a fairly regular basis….. then crickets. Perhaps the hiatus is over with the approval
Once in a while it is good to believe in facts.The brief article below deserves some serious attention as it includes some really positive facts
Specialty pharmacy under Medicaid is a bellwether for making observations on the broader specialty market and where the market is headed. Since Medicaid is state
I’ve been ringing the alarm bell for several years now alerting the specialty pharmacy industry that it was under attack by health system owned specialty
